Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Bioheart, Inc. announced positive efficacy data has been reported from the registry study of bone marrow and adipose derived stem cells for the treatment of end stage critical limb ischemia with wounds. Vaclav Prochazka MD, PhD, MSc., of University Hospital Ostrava, Czech Republic presented data at the American Academy of Anti-Aging Medicine Conference in Las Vegas last month.

10 Jan 2011

Scientists identify type of cell at the origin of brain tumors

Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas, which are a type of glioma - a category that defines the most common type of malignant brain tumor.

7 Jan 2011

Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.

7 Jan 2011

StemCells $10 million common stock offering to close today

StemCells, Inc. announced today that it has entered into an agreement to sell ten million shares of its common stock to selected institutional investors at a price of $1.00 per share, which represents a 10% discount to the closing price per share of January 6. The offering is expected to close today, subject to customary closing conditions, and StemCells expects to receive net proceeds, after deducting offering expenses and fees, of approximately $9.4 million.

7 Jan 2011

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas), for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV).

7 Jan 2011

Cells that give rise to neurons maintain high levels of ROS

For years, the majority of research on reactive oxygen species (ROS) - ions or very small molecules that include free radicals - has focused on how they damage cell structure and their potential link to stroke, cardiovascular disease and other illnesses.

7 Jan 2011

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Athersys, Inc. today announced that it has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem to patients being treated for leukemia or other blood born cancers.

7 Jan 2011

Study: Tβ4 can protect endothelial progenitor cells

RegeneRx Biopharmaceuticals, reported that a team of cardiovascular researchers in China have shown that Tβ4 can protect endothelial progenitor cells derived from the blood of healthy human volunteers.

7 Jan 2011

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

Elevated fat and cholesterol levels found in a typical American-style diet play an important role in the growth and spread of breast cancer, say researchers at the Kimmel Cancer Center at Jefferson.

7 Jan 2011

Researchers discover specific genetic abnormalities in hESC, iPSC lines

A multinational team of researchers led by stem cell scientists at the University of California, San Diego School of Medicine and Scripps Research Institute has documented specific genetic abnormalities that occur in human embryonic and induced pluripotent stem cell lines.

7 Jan 2011

Robo4 molecule may improve bone marrow transplants: Study

Researchers at the University of California, Santa Cruz, have identified a key molecule for establishing blood stem cells in their niche within the bone marrow. The findings, reported in the January issue of Cell Stem Cell, may lead to improvements in the safety and efficiency of bone marrow transplants.

7 Jan 2011

Researchers regenerate complete shoulder joint surfaces using patient's own cells

Artificial joint replacements can drastically change a patient's quality of life. Painful, arthritic knees, shoulders and hips can be replaced with state-of-the-art metal or ceramic implants, eliminating pain and giving a person a new lease on life.

6 Jan 2011

Transposagen, CDI enter license agreement for iPS cell line production

Transposagen Biopharmaceuticals, a leader in genetic modification technology, announced today that it has entered into a non-exclusive license agreement with Cellular Dynamics International, the world's largest producer of human induced pluripotent stem cell lines and tissue cells for drug discovery and safety.

6 Jan 2011

Researchers investigate umbilical cord blood stem cells for traumatic brain injury in children

The University of Texas Health Science Center at Houston has begun enrollment for the first Phase I safety study approved by the Food and Drug Administration to investigate the use of a child's own umbilical cord blood stem cells for traumatic brain injury in children.

6 Jan 2011

Defect in conversion of hair follicle stem cells to progenitor cells linked to male-pattern baldness

Androgenetic alopecia (AGA) is a frequent form of hair loss in both men and women. However, it is more common in men, in whom it is also known as male-pattern baldness.

5 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

ReproCELL to enter collaborative iPS cell-derived hepatocytes R&D agreement with NIBIO

ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company will enter a collaborative R&D agreement with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan), which could offer new hepatocyte derived from human iPS (induced pluripotent stem) cells used for an effective in-vitro drug screening for hepatic toxicity and liver metabolism.

5 Jan 2011

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc., a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma's ATIR™.

5 Jan 2011

Study: Stem cells play an unexpected role in male pattern balding

Given the amount of angst over male pattern balding, surprisingly little is known about its cause at the cellular level. In a new study, published in the Journal of Clinical Investigation, a team led by George Cotsarelis, MD, chair of the Department of Dermatology at the University of Pennsylvania School of Medicine, has found that stem cells play an unexpected role in explaining what happens in bald scalp.

5 Jan 2011

FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) amendment to conduct a Phase II clinical trial in the U.S. of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

4 Jan 2011

Stem Cells News and Research

Further Reading

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Scientists identify type of cell at the origin of brain tumors

Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

StemCells $10 million common stock offering to close today

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cells that give rise to neurons maintain high levels of ROS

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Study: Tβ4 can protect endothelial progenitor cells

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

Researchers discover specific genetic abnormalities in hESC, iPSC lines

Robo4 molecule may improve bone marrow transplants: Study

Researchers regenerate complete shoulder joint surfaces using patient's own cells

Transposagen, CDI enter license agreement for iPS cell line production

Researchers investigate umbilical cord blood stem cells for traumatic brain injury in children

Defect in conversion of hair follicle stem cells to progenitor cells linked to male-pattern baldness

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

ReproCELL to enter collaborative iPS cell-derived hepatocytes R&D agreement with NIBIO

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Study: Stem cells play an unexpected role in male pattern balding

FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial

eBook: Integrated solutions for mesenchymal stem cell research and culture eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo